Other News To Note

MolMed SpA, of Milan, Italy, signed an agreement with GlaxoSmithKline plc, of London, and will develop a production process for an investigational gene therapy for adenosine deaminase deficiency-severe combined immune deficiency, a rare, life-threatening disease that affects approximately 350 children worldwide. MolMed said it will receive as much as $7.78 million in revenue over a two-year period.